Madrigal Pharmaceuticals Inc (MDGL)

$546.66 +12.50 (2.34%)
Market Cap 12.34B
Revenue (ttm) 958.40M
Net Income (ttm) -288.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -30.08%
Debt to Equity Ratio 0.65
Volume 281,200
Avg Vol 311,230
Day's Range N/A - N/A
Shares Out 23.10M
Stochastic %K 81%
Beta -0.98
Analysts Strong Sell
Price Target $670.89

Company Profile

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Industry: Biotechnology
Sector: Healthcare
Phone: 267 824 2827
Address:
1001 Conshohocken State Road, Suite 2-350, West Conshohocken, United States
Wallst45
Wallst45 Sep. 9 at 10:07 PM
$MDGL presenting data tomorrow ✈️
0 · Reply
Wallst45
Wallst45 Sep. 9 at 10:06 PM
$MDGL shorts will be forced to cover on buyout rumors
0 · Reply
forprofit12
forprofit12 Sep. 9 at 8:24 PM
$MDGL short interest was really down. Do you think it went back up?
1 · Reply
Live2ride
Live2ride Sep. 9 at 8:07 PM
$MDGL Another stab at the $550 level today. Can't wait until this breaks to the upside and the shorts are forced to cover.
0 · Reply
Wallst45
Wallst45 Sep. 9 at 7:39 PM
$MDGL what is this strength today ??
0 · Reply
Wallst45
Wallst45 Sep. 9 at 4:02 PM
$MDGL market sinking and we holding nice green.
0 · Reply
Wallst45
Wallst45 Sep. 9 at 3:30 PM
$MDGL Big Pharma more dependent on commercial companies now
1 · Reply
forprofit12
forprofit12 Sep. 9 at 1:45 PM
$MDGL tell me something new. Same thing everyday.
1 · Reply
HamBoneXoXo
HamBoneXoXo Sep. 8 at 12:50 PM
$MDGL Nearly every biotech that gets an approved drug suddenly becomes an M&A fantacy. The long term stats on that is 60%. Not a percentage to invest based on.
0 · Reply
forprofit12
forprofit12 Sep. 4 at 3:12 PM
$MDGL don’t think so. But do have a great long weekend.
1 · Reply
Latest News on MDGL
Madrigal Pharmaceuticals to Participate in the  2026 Cantor Global Healthcare Conference

Sep 2, 2026, 8:00 AM EDT - 7 days ago

Madrigal Pharmaceuticals to Participate in the  2026 Cantor Global Healthcare Conference

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Aug 20, 2026, 4:05 PM EDT - 20 days ago

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Appoints John C. Reed, M.D.

Aug 12, 2026, 8:00 AM EDT - 4 weeks ago

Madrigal Appoints John C. Reed, M.D.

Madrigal Pharmaceuticals Transcript: Canaccord Genuity's 46th Annual Growth Conference

Aug 11, 2026, 12:00 PM EDT - 4 weeks ago

Madrigal Pharmaceuticals Transcript: Canaccord Genuity's 46th Annual Growth Conference

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2026, 8:00 AM EDT - 4 weeks ago

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Madrigal upgraded to Outperform from Peer Perform at Wolfe Research

2026-08-04T09:25:27.000Z - 5 weeks ago

Madrigal upgraded to Outperform from Peer Perform at Wolfe Research

Madrigal Pharmaceuticals price target lowered to $962 from $964 at Barclays

2026-08-03T09:45:49.000Z - 5 weeks ago

Madrigal Pharmaceuticals price target lowered to $962 from $964 at Barclays

Madrigal Pharmaceuticals price target lowered to $543 from $553 at BofA

2026-07-31T12:46:17.000Z - 5 weeks ago

Madrigal Pharmaceuticals price target lowered to $543 from $553 at BofA

Madrigal Pharmaceuticals Earnings Call Transcript: Q2 2026

Jul 30, 2026, 8:00 AM EDT - 5 weeks ago

Madrigal Pharmaceuticals Earnings Call Transcript: Q2 2026

Madrigal Pharmaceuticals Earnings release: Q2 2026

Jul 30, 2026, 8:00 AM EDT - 5 weeks ago

Madrigal Pharmaceuticals Earnings release: Q2 2026

Madrigal Pharmaceuticals Slides: Q2 2026

Jul 30, 2026, 8:00 AM EDT - 5 weeks ago

Madrigal Pharmaceuticals Slides: Q2 2026

Madrigal Pharmaceuticals Quarterly report: Q2 2026

Jul 30, 2026, 8:00 AM EDT - 5 weeks ago

Madrigal Pharmaceuticals Quarterly report: Q2 2026

Madrigal Pharmaceuticals reports Q2 EPS ($1.99), consensus ($2.23)

2026-07-30T11:33:34.000Z - 5 weeks ago

Madrigal Pharmaceuticals reports Q2 EPS ($1.99), consensus ($2.23)

Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates

Jul 30, 2026, 7:00 AM EDT - 5 weeks ago

Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates

Madrigal Pharmaceuticals price target raised to $587 from $578 at Canaccord

2026-07-29T11:21:18.000Z - 6 weeks ago

Madrigal Pharmaceuticals price target raised to $587 from $578 at Canaccord

Madrigal Pharmaceuticals initiated with an Overweight at Wells Fargo

2026-07-27T09:25:16.000Z - 6 weeks ago

Madrigal Pharmaceuticals initiated with an Overweight at Wells Fargo

Madrigal Pharmaceuticals price target raised to $553 from $542 at BofA

2026-07-22T13:06:15.000Z - 7 weeks ago

Madrigal Pharmaceuticals price target raised to $553 from $542 at BofA

Madrigal Pharmaceuticals price target raised to $739 from $737 at Citizens

2026-07-17T09:20:14.000Z - 7 weeks ago

Madrigal Pharmaceuticals price target raised to $739 from $737 at Citizens

Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026

Jul 16, 2026, 8:00 AM EDT - 7 weeks ago

Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026

Madrigal Pharmaceuticals announces three new resmetirom patents

2026-07-13T12:05:19.000Z - 1 month ago

Madrigal Pharmaceuticals announces three new resmetirom patents

Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio

Jul 13, 2026, 8:00 AM EDT - 1 month ago

Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio

Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH

Jul 1, 2026, 9:19 PM EDT - 2 months ago

Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH

Madrigal Pharmaceuticals management to meet with Piper Sandler

2026-06-17T20:21:37.000Z - 2 months ago

Madrigal Pharmaceuticals management to meet with Piper Sandler

Madrigal Pharmaceuticals price target lowered to $542 from $550 at BofA

2026-06-11T10:41:26.000Z - 3 months ago

Madrigal Pharmaceuticals price target lowered to $542 from $550 at BofA

Madrigal Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 10, 2026, 11:20 AM EDT - 3 months ago

Madrigal Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026

Jun 3, 2026, 8:00 AM EDT - 3 months ago

Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026

Madrigal Pharmaceuticals announces new analyses of Rezdiffra data

2026-05-27T14:23:26.000Z - 3 months ago

Madrigal Pharmaceuticals announces new analyses of Rezdiffra data

Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH

May 27, 2026, 8:00 AM EDT - 3 months ago

Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH

Madrigal to Present New Data from the Company's MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk

May 20, 2026, 8:00 AM EDT - 3 months ago

Madrigal to Present New Data from the Company's MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk

Madrigal Pharmaceuticals price target raised to $709 from $640 at Truist

2026-05-13T13:52:07.000Z - 3 months ago

Madrigal Pharmaceuticals price target raised to $709 from $640 at Truist

Madrigal Pharmaceuticals price target lowered to $578 from $587 at Canaccord

2026-05-07T16:42:06.000Z - 4 months ago

Madrigal Pharmaceuticals price target lowered to $578 from $587 at Canaccord

Madrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI

2026-05-07T13:49:17.000Z - 4 months ago

Madrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI

Madrigal Pharmaceuticals reports Q1 EPS ($3.25), consensus ($4.14)

2026-05-07T07:31:11.000Z - 4 months ago

Madrigal Pharmaceuticals reports Q1 EPS ($3.25), consensus ($4.14)

Madrigal Pharmaceuticals price target raised to $680 from $533 at Clear Street

2026-05-07T00:53:12.000Z - 4 months ago

Madrigal Pharmaceuticals price target raised to $680 from $533 at Clear Street

Madrigal Pharmaceuticals Earnings Call Transcript: Q1 2026

May 6, 2026, 8:00 AM EDT - 4 months ago

Madrigal Pharmaceuticals Earnings Call Transcript: Q1 2026

Madrigal Pharmaceuticals Earnings release: Q1 2026

May 6, 2026, 8:00 AM EDT - 4 months ago

Madrigal Pharmaceuticals Earnings release: Q1 2026

Madrigal Pharmaceuticals Slides: Q1 2026

May 6, 2026, 8:00 AM EDT - 4 months ago

Madrigal Pharmaceuticals Slides: Q1 2026

Madrigal Pharmaceuticals Quarterly report: Q1 2026

May 6, 2026, 8:00 AM EDT - 4 months ago

Madrigal Pharmaceuticals Quarterly report: Q1 2026

Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates

May 6, 2026, 7:00 AM EDT - 4 months ago

Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates

Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline

May 5, 2026, 8:00 AM EDT - 4 months ago

Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

May 5, 2026, 8:00 AM EDT - 4 months ago

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

ARWR

Madrigal Pharmaceuticals Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Madrigal Pharmaceuticals Proxy statement: Proxy filing

Madrigal Pharmaceuticals Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Madrigal Pharmaceuticals Proxy statement: Proxy filing

Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026

Madrigal Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 2:30 PM EST - 6 months ago

Madrigal Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 6 months ago

Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

Madrigal Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 19, 2026, 8:00 AM EST - 6 months ago

Madrigal Pharmaceuticals Earnings Call Transcript: Q4 2025

Madrigal Pharmaceuticals Annual report: Q4 2025

Feb 19, 2026, 8:00 AM EST - 6 months ago

Madrigal Pharmaceuticals Annual report: Q4 2025

Madrigal Pharmaceuticals Earnings release: Q4 2025

Feb 19, 2026, 8:00 AM EST - 6 months ago

Madrigal Pharmaceuticals Earnings release: Q4 2025

Madrigal Pharmaceuticals Slides: Q4 2025

Feb 19, 2026, 8:00 AM EST - 6 months ago

Madrigal Pharmaceuticals Slides: Q4 2025

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results

Feb 19, 2026, 7:00 AM EST - 6 months ago

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results

Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

Feb 11, 2026, 6:25 AM EST - 7 months ago

Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs

Feb 11, 2026, 5:00 AM EST - 7 months ago

Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026

Feb 2, 2026, 8:05 AM EST - 7 months ago

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026

Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)

Jan 21, 2026, 4:05 PM EST - 7 months ago

Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)

Madrigal Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 4:30 PM EST - 8 months ago

Madrigal Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Madrigal Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 4:30 PM EST - 8 months ago

Madrigal Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

Jan 9, 2026, 8:00 AM EST - 8 months ago

Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 15, 2025, 4:05 PM EST - 8 months ago

Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Madrigal Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 1:30 PM EST - 9 months ago

Madrigal Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Madrigal Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 4:15 PM EST - 9 months ago

Madrigal Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Madrigal Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 20, 2025, 3:30 AM EST - 9 months ago

Madrigal Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

Nov 17, 2025, 8:00 AM EST - 9 months ago

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis

Nov 10, 2025, 8:00 AM EST - 10 months ago

Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis

Madrigal Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 10 months ago

Madrigal Pharmaceuticals Earnings Call Transcript: Q3 2025

Madrigal Pharmaceuticals Quarterly report: Q3 2025

Nov 4, 2025, 8:00 AM EST - 10 months ago

Madrigal Pharmaceuticals Quarterly report: Q3 2025

Madrigal Pharmaceuticals Earnings release: Q3 2025

Nov 4, 2025, 8:00 AM EST - 10 months ago

Madrigal Pharmaceuticals Earnings release: Q3 2025

Madrigal Pharmaceuticals Slides: Q3 2025

Nov 4, 2025, 8:00 AM EST - 10 months ago

Madrigal Pharmaceuticals Slides: Q3 2025

Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates

Nov 4, 2025, 7:00 AM EST - 10 months ago

Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Nov 3, 2025, 9:58 AM EST - 10 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MEDI

Madrigal to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025

Oct 28, 2025, 8:00 AM EDT - 10 months ago

Madrigal to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025

Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025

Oct 22, 2025, 8:00 AM EDT - 10 months ago

Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025

Madrigal Pharma CEO talks competition in the liver disease treatment space

Oct 16, 2025, 6:18 PM EDT - 10 months ago

Madrigal Pharma CEO talks competition in the liver disease treatment space

Madrigal Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 7:45 AM EDT - 1 year ago

Madrigal Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Madrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference

Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Aug 19, 2025, 4:05 PM EDT - 1 year ago

Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Madrigal Pharmaceuticals Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 12, 2025, 10:30 AM EDT - 1 year ago

Madrigal Pharmaceuticals Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Madrigal Pharmaceuticals CEO: We're positioned for decades of growth

Aug 8, 2025, 6:15 PM EDT - 1 year ago

Madrigal Pharmaceuticals CEO: We're positioned for decades of growth

Madrigal Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Earnings Call Transcript: Q2 2025

Madrigal Pharmaceuticals Quarterly report: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Quarterly report: Q2 2025

Madrigal Pharmaceuticals Earnings release: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Earnings release: Q2 2025

Madrigal Pharmaceuticals Slides: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Slides: Q2 2025

Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates

Aug 5, 2025, 7:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

Jul 30, 2025, 5:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025

Jul 25, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025

Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH

Jul 22, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH

Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)

Jul 16, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)

Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra Approval

Jun 20, 2025, 7:35 AM EDT - 1 year ago

Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra Approval

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Jun 20, 2025, 6:30 AM EDT - 1 year ago

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Madrigal Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 11, 2025, 10:40 AM EDT - 1 year ago

Madrigal Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference

Madrigal Pharmaceuticals Transcript: Status Update

May 13, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Transcript: Status Update

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

May 10, 2025, 7:15 AM EDT - 1 year ago

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

Madrigal Pharmaceuticals Earnings Call Transcript: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Earnings Call Transcript: Q1 2025

Madrigal Pharmaceuticals Quarterly report: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Quarterly report: Q1 2025

Madrigal Pharmaceuticals Earnings release: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Earnings release: Q1 2025

Madrigal Pharmaceuticals Slides: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Slides: Q1 2025

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

May 1, 2025, 7:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress

Madrigal Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Proxy statement: Proxy Filing

Madrigal Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Proxy statement: Proxy Filing

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025

Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D.

Apr 16, 2025, 7:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D.

Madrigal Appoints Jacqualyn A. Fouse, Ph.D.

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Madrigal Appoints Jacqualyn A. Fouse, Ph.D.

Madrigal Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 11:10 AM EST - 1 year ago

Madrigal Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Madrigal CEO on Q4 earnings beat, MASH drug market opportunity

Feb 26, 2025, 6:33 PM EST - 1 year ago

Madrigal CEO on Q4 earnings beat, MASH drug market opportunity

Madrigal Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 26, 2025, 8:00 AM EST - 1 year ago

Madrigal Pharmaceuticals Earnings Call Transcript: Q4 2024

Madrigal Pharmaceuticals Annual report: Q4 2024

Feb 26, 2025, 8:00 AM EST - 1 year ago

Madrigal Pharmaceuticals Annual report: Q4 2024

Madrigal Pharmaceuticals Earnings release: Q4 2024

Feb 26, 2025, 8:00 AM EST - 1 year ago

Madrigal Pharmaceuticals Earnings release: Q4 2024

Madrigal Pharmaceuticals Slides: Q4 2024

Feb 26, 2025, 8:00 AM EST - 1 year ago

Madrigal Pharmaceuticals Slides: Q4 2024

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Feb 26, 2025, 7:00 AM EST - 1 year ago

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Wallst45
Wallst45 Sep. 9 at 10:07 PM
$MDGL presenting data tomorrow ✈️
0 · Reply
Wallst45
Wallst45 Sep. 9 at 10:06 PM
$MDGL shorts will be forced to cover on buyout rumors
0 · Reply
forprofit12
forprofit12 Sep. 9 at 8:24 PM
$MDGL short interest was really down. Do you think it went back up?
1 · Reply
Live2ride
Live2ride Sep. 9 at 8:07 PM
$MDGL Another stab at the $550 level today. Can't wait until this breaks to the upside and the shorts are forced to cover.
0 · Reply
Wallst45
Wallst45 Sep. 9 at 7:39 PM
$MDGL what is this strength today ??
0 · Reply
Wallst45
Wallst45 Sep. 9 at 4:02 PM
$MDGL market sinking and we holding nice green.
0 · Reply
Wallst45
Wallst45 Sep. 9 at 3:30 PM
$MDGL Big Pharma more dependent on commercial companies now
1 · Reply
forprofit12
forprofit12 Sep. 9 at 1:45 PM
$MDGL tell me something new. Same thing everyday.
1 · Reply
HamBoneXoXo
HamBoneXoXo Sep. 8 at 12:50 PM
$MDGL Nearly every biotech that gets an approved drug suddenly becomes an M&A fantacy. The long term stats on that is 60%. Not a percentage to invest based on.
0 · Reply
forprofit12
forprofit12 Sep. 4 at 3:12 PM
$MDGL don’t think so. But do have a great long weekend.
1 · Reply
1986iamwallstreet
1986iamwallstreet Sep. 4 at 2:50 PM
$MDGL market cap is small and growth is big 🚀
1 · Reply
1986iamwallstreet
1986iamwallstreet Sep. 4 at 2:50 PM
$MDGL 👀🚀🚀🚀🚀🚀🚀🚀
0 · Reply
Wallst45
Wallst45 Sep. 4 at 2:24 PM
$MDGL Long Weekend Vibes. M&A vibes back
1 · Reply
Wallst45
Wallst45 Sep. 3 at 8:36 PM
$MDGL getting closer to buyout and funds have 99.9% of position in this company
1 · Reply
Live2ride
Live2ride Sep. 3 at 6:42 PM
$MDGL Anemic volume. Less than 70k shares with a little over an hour til the close. Need some new funds to step up and hit buy at the ask button.
1 · Reply
Wallst45
Wallst45 Sep. 2 at 7:55 PM
$MDGL Rippy into Close
1 · Reply
Wallst45
Wallst45 Sep. 2 at 4:20 PM
$MDGL can we squeeze above 550 today ?
0 · Reply
Live2ride
Live2ride Sep. 2 at 1:40 PM
$MDGL Can we take out $550/$560 please? TIA
0 · Reply
DickHardy
DickHardy Sep. 1 at 1:33 PM
$MDGL I think we are going to continue to buy or partner with other companies in the future. I have been doing my research and think that we should buy $GALT . We could probably buy them for less than $1 billion and it would help us with F4 and the competition. Strengthen our ownership of the entire continuum of care for MASH
6 · Reply
Wallst45
Wallst45 Aug. 31 at 7:55 PM
$MDGL nice squeeze into close
0 · Reply
ReapN
ReapN Aug. 31 at 5:46 AM
$SLS just look at this Monopoly named $MDGL hold your gold Follow the money, MDGL used to be small too. Madrigal Institutional Holdings Citadel is LONG &
0 · Reply
forprofit12
forprofit12 Aug. 29 at 12:53 AM
$AXSM $MDGL two of my biggest holdings and suffering the same fate. Increase expenses to capture market share and market punishing. Not sure when they will turn around but I believe they eventually will. The wait is annoying though.
2 · Reply